SCHEMBL20094301

SCHEMBL20094301

Cc1nc2ccc(C(F)(F)F)c(-c3cc(Cl)c4[nH]ncc4c3)n2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 7/20 0.43
ADORA2A P29274 3/20 0.43
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
TRPM8 Q7Z2W7 3/20 0.34
TRPV1 Q8NER1 2/20 0.34
RPS6KB1 P23443 1/20 0.33
ROCK1 Q13464 1/20 0.33
RPS6KA1 Q15418 1/20 0.33
NOS1 P29475 1/20 0.33
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
PIK3CG P48736 1/20 0.32
NOTUM Q6P988 2/20 0.31
TNF P01375 1/20 0.31
NPC1 O15118 1/20 0.31
PKM P14618 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20094365 0.89 ADORA2A (0.39) TRPA1ADORA2ARXRARXRBRXRG
SCHEMBL20094264 0.89 TRPA1 (0.56) TRPA1ADORA2ARXRARXRBRXRG
SCHEMBL20094527 0.89 ADORA2A (0.40) TRPA1ADORA2ARXRARXRBRXRG
SCHEMBL20094634 0.88 TRPA1 (0.38) TRPA1ADORA2ARXRARXRBRXRG
SCHEMBL20094652 0.88 ADORA2A (0.39) TRPA1ADORA2ARXRARXRBRXRG
SCHEMBL20094658 0.88 TRPA1 (0.38) TRPA1ADORA2ARXRARXRBRXRG
SCHEMBL20088574 0.86 ADORA2A (0.46) TRPA1ADORA2ANOS1
SCHEMBL20094351 0.86 ADORA2A (0.38) TRPA1ADORA2ARXRARXRBRXRG
SCHEMBL20094273 0.85 TRPA1 (0.36) TRPA1ADORA2ARXRARXRBRXRG
SCHEMBL20088604 0.84 ADORA2A (0.40) TRPA1ADORA2ARXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3532477-B1 FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-08-26 EP claimed
EP-3532477-B1 FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-08-26 EP disclosed
WO-2018080917-A1 FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 WO disclosed
US-20180111933-A1 FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111933-A1 FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN3A, GRM1 TRPA1 593/4885ADORA2A 186/4885RXRA 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.